FDA has evaluated the following bulk drug substances and determined that there is a clinical need for outsourcing facilities to compound drug products using these bulk drug substances under section 503B of the FD&C Act: One key condition: Facility generally cannot compound drugs using bulk drug substances unless that substance appears on the FDA's '503B Bulks List' (substances for which there is a demonstrated clinical need) or the compounded drug is on the FDA's active drug shortage list
Hirsch IB
It also reduces the formation of plaque in the arteries by lowering cholesterol levels and channeling them to the mitochondria for energy generation
Why Delivery Format Matters You might wonder why you cant just take a high-dose powder and call it a day
Crisafulli S, Alkabbani W, Paik JM, Bykov K, Tavakkoli A, Glynn RJ, Htoo PT, Yu EW, Trifir G, Wexler DJ, Patorno E
Drewes JL, Housseau F, Sears CL